Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment.
HIV
cognitive impairment
multivariate
neuroimaging
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
20
03
2019
accepted:
25
04
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
3
7
2019
Statut:
epublish
Résumé
The optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient- reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts. Differences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria. The prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment ( Different methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach.
Sections du résumé
BACKGROUND
BACKGROUND
The optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient- reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts.
METHODS
METHODS
Differences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria.
RESULTS
RESULTS
The prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment (
CONCLUSION
CONCLUSIONS
Different methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach.
Identifiants
pubmed: 31263729
doi: 10.1093/ofid/ofz198
pii: ofz198
pmc: PMC6590980
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz198Subventions
Organisme : NIMH NIH HHS
ID : HHSN271201000030C
Pays : United States
Organisme : NIMH NIH HHS
ID : HHSN271201000036C
Pays : United States
Organisme : Department of Health
ID : NIHR-RP-011-048
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M004236/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : N01 MH022005
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Investigateurs
P Reiss
(P)
F W N M Wit
(FWNM)
J Schouten
(J)
K W Kooij
(KW)
R A van Zoest
(RA)
B C Elsenga
(BC)
F R Janssen
(FR)
M Heidenrijk
(M)
W Zikkenheiner
(W)
M van der Valk
(M)
N A Kootstra
(NA)
A M Harskamp-Holwerda
(AM)
I Maurer
(I)
M M Mangas Ruiz
(MM)
A F Girigorie
(AF)
J Villaudy
(J)
E Frankin
(E)
A Pasternak
(A)
B Berkhout
(B)
T van der Kuyl
(T)
P Portegies
(P)
B A Schmand
(BA)
G J Geurtsen
(GJ)
J A Ter Stege
(JA)
M Klein Twennaar
(M)
C B L M Majoie
(CBLM)
M W A Caan
(MWA)
T Su
(T)
K Weijer
(K)
P H L T Bisschop
(PHLT)
A Kalsbeek
(A)
M Wezel
(M)
I Visser
(I)
H G Ruhé
(HG)
C Franceschi
(C)
P Garagnani
(P)
C Pirazzini
(C)
M Capri
(M)
F Dall'Olio
(F)
M Chiricolo
(M)
S Salvioli
(S)
J Hoeijmakers
(J)
J Pothof
(J)
M Prins
(M)
M Martens
(M)
S Moll
(S)
J Berkel
(J)
M Totté
(M)
S Kovalev
(S)
M Gisslén
(M)
D Fuchs
(D)
H Zetterberg
(H)
A Winston
(A)
J Underwood
(J)
L McDonald
(L)
M Stott
(M)
K Legg
(K)
A Lovell
(A)
O Erlwein
(O)
N Doyle
(N)
C Kingsley
(C)
D J Sharp
(DJ)
R Leech
(R)
J H Cole
(JH)
S Zaheri
(S)
M M J Hillebregt
(MMJ)
Y M C Ruijs
(YMC)
D P Benschop
(DP)
D Burger
(D)
M de Graaff-Teulen
(M)
G Guaraldi
(G)
A Bürkle
(A)
T Sindlinger
(T)
M Moreno-Villanueva
(M)
A Keller
(A)
C Sabin
(C)
D de Francesco
(D)
C Libert
(C)
S Dewaele
(S)
Marta Boffito
(M)
Paddy Mallon
(P)
Frank Post
(F)
Caroline Sabin
(C)
Memory Sachikonye
(M)
Alan Winston
(A)
Jane Anderson
(J)
David Asboe
(D)
Marta Boffito
(M)
Lucy Garvey
(L)
Paddy Mallon
(P)
Frank Post
(F)
Anton Pozniak
(A)
Caroline Sabin
(C)
Memory Sachikonye
(M)
Jaime Vera
(J)
Ian Williams
(I)
Alan Winston
(A)
Frank Post
(F)
Lucy Campbell
(L)
Selin Yurdakul
(S)
Sara Okumu
(S)
Louise Pollard
(L)
Ian Williams
(I)
Damilola Otiko
(D)
Laura Phillips
(L)
Rosanna Laverick
(R)
Martin Fisher
(M)
Amanda Clarke
(A)
Jaime Vera
(J)
Andrew Bexley
(A)
Celia Richardson
(C)
Paddy Mallon
(P)
Alan Macken
(A)
Bijan Ghavani-Kia
(B)
Joanne Maher
(J)
Maria Byrne
(M)
Ailbhe Flaherty
(A)
Jane Anderson
(J)
Sifiso Mguni
(S)
Rebecca Clark
(R)
Rhiannon Nevin-Dolan
(R)
Sambasivarao Pelluri
(S)
Margaret Johnson
(M)
Nnenna Ngwu
(N)
Nargis Hemat
(N)
Martin Jones
(M)
Anne Carroll
(A)
Andrew Whitehouse
(A)
Laura Burgess
(L)
Daphne Babalis
(D)
Alan Winston
(A)
Lucy Garvey
(L)
Jonathan Underwood
(J)
Matthew Stott
(M)
Linda McDonald
(L)
Marta Boffito
(M)
David Asboe
(D)
Anton Pozniak
(A)
Chris Higgs
(C)
Elisha Seah
(E)
Stephen Fletcher
(S)
Michelle Anthonipillai
(M)
Ashley Moyes
(A)
Katie Deats
(K)
Irtiza Syed
(I)
Clive Matthews
(C)
Références
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):120-7
pubmed: 24991974
Neuroimage. 2011 Apr 15;55(4):1577-86
pubmed: 21256236
Clin Infect Dis. 2017 Aug 01;65(3):422-432
pubmed: 28387814
AIDS. 2007 Sep 12;21(14):1915-21
pubmed: 17721099
J Neurovirol. 2011 Jun;17(3):248-57
pubmed: 21544705
J Int Neuropsychol Soc. 2001 Nov;7(7):867-74
pubmed: 11771630
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Clin Exp Neuropsychol. 2004 May;26(3):307-19
pubmed: 15512922
HIV Med. 2017 May;18(5):363-369
pubmed: 27785907
J Infect Dis. 2017 Dec 27;217(1):69-81
pubmed: 29069436
Neuroimage. 2009 Jan 1;44(1):83-98
pubmed: 18501637
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Neuroimage. 2014 May 15;92:381-97
pubmed: 24530839
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Neurovirol. 2011 Apr;17(2):159-65
pubmed: 21437751
BMC Infect Dis. 2011 Dec 28;11:356
pubmed: 22204557
Neurology. 2017 Apr 4;88(14):1349-1357
pubmed: 28258081
Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e
pubmed: 29746638
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Ann Neurol. 2015 Apr;77(4):571-81
pubmed: 25623048
PLoS One. 2018 Mar 29;13(3):e0191791
pubmed: 29596425
AIDS. 2016 Jan;30(2):311-22
pubmed: 26691551
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
AIDS. 2015 Mar 13;29(5):547-57
pubmed: 25587908
J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):429-436
pubmed: 29608444
PLoS One. 2018 Apr 11;13(4):e0194760
pubmed: 29641619
Clin Infect Dis. 2014 Dec 15;59(12):1787-97
pubmed: 25182245